Ycanth receives permanent J-code from CMS

Key takeaways:

• Ycanth has received a permanent J-code for the treatment of molluscum contagiosum.
• The code will be fully published April 1, 2024.

Ycanth has received a permanent J-code from the Centers for Medicare & Medicaid Services, Verrica Pharmaceuticals announced in a press release.

Approved by the FDA for the treatment of molluscum contagiosum in July 2023, Ycanth topical solution is a proprietary drug-device combination product that contains cantharidin 0.7%, which is delivered via a single-use applicator.

J-codes are a type of level II code in the Healthcare Common Procedure Coding System used to designate non-orally administered drugs and other medical devices to help determine how medical providers can be reimbursed for products and services.

“By securing a permanent J-Code for Ycanth, we have successfully reached a critical milestone in our commercial strategy that we expect will help us accelerate Ycanth utilization among the U.S. Medicaid and Medicare patient populations,” Ted White, president and CEO of Verrica Pharmaceuticals, said in the release. “In addition to greater patient access, we also anticipate a permanent J-Code will result in a more streamlined billing and reimbursement process for Ycanth.”

The J-code for Ycanth will become fully published on April 1, 2024.